

Therapeutic preparations containing quinazoline derivatives.

Patent Number: EP0520722

Publication
date: 1992-12-30

Inventor(s): BARKER ANDREW JOHN (GB); DAVIES DAVID HUW (GB)

Applicant(s):: ICI PLC (GB)

Requested
Patent: ☐ EP0520722, B1Application
Number: EP19920305703 19920622Priority Number
(s): GB19910013970 19910628; GB19920001133 19920120IPC
Classification: A61K31/505 ; C07D239/94EC
Classification: C07D239/94Equivalents: AU1842292, AU651215, CA2071087, CZ9201827, DE69216158D, DE69216158T,
FI922785, GR3022167T, HU61290, ☐ IE921799, IL102204, ☐ JP5208911,
NO180105B, NO180105C, NZ243082, SK182792**Abstract**

The invention concerns a pharmaceutical composition which comprises known or novel quinazoline derivatives of the formula I wherein, for example, R<1> is hydrogen, trifluoromethyl or nitro, n is 1 and R<2> is halogeno, trifluoromethyl, nitro, cyano, (1-4C)alkyl, (1-4C)alkoxy, N-(1-4C)alkylamino, N,N-di-((1-4C)alkyl)amino, (1-4C)alkylthio, (1-4C)alkylsulphanyl or (1-4C)alkylsulphonyl; and pharmaceutically-acceptable diluents or carriers thereof; the novel quinazoline derivatives and a process for their preparation; and the use of the receptor tyrosine kinase inhibitory properties of both the known and novel quinazoline derivatives in the treatment of cancer.

Data supplied from the esp@cenet database - I2

— Please see exhibit 32 —